Penn Medicine Abramson Cancer Center


 

Penn Updates on CML: Do Cancer-Related Mutational Events at Diagnosis Predict Inferior Outcomes? Is Ponatinib Effective & Safe? Is Asciminib More Beneficial vs. Bosutinib in CP-CML Treated With > TKIs?

0 views
March 2, 2021
Comments 0
Login to view comments. Click here to Login